Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Abbott Labs (ABT - Analyst Report) recently announced that it has obtained the CE Marking (Conformite Europeenne) in Europe for its glucose monitoring system – FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System.

The CE mark is a mandatory confirmation for products placed in the European markets.

In Jul 2013, Abbott Labs obtained the U.S. Food and Drug Administration (FDA) clearance for its FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System.

We note that Abbott Labs continues to invest in the development of innovative technologies in its diabetes care business.  The company is currently investing in the next-generation sensing technology which it expects to initially launch in the European markets in the second half of 2014.

Abbott Labs expects diabetes care sales growth to be relatively flat in the third quarter of 2013.

Although growth in the emerging markets is forecasted to be strong, Abbott Labs expects the implementation of Centers for Medicare and Medicaid Services (CMS) competitive bidding for Medicare patients to impact sales in the U.S. in the remainder of the year.

Sales from diabetes care business declined marginally in the second quarter of 2013. Share gains in the hospital and retail units in the U.S. were offset by market pricing and reimbursement pressures. International sales climbed 4% driven by the continued uptake of FreeStyle InsuLinx Meter along with growth in the emerging markets continues to positively impact sales in international markets.

We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. (ABBV - Analyst Report), in Jan 2013.

We believe the diversification bodes well for Abbott Labs and should enable the company to counter the challenging business environment as a result of austerity measures undertaken by developed markets in 2013 coupled with weak economic conditions elsewhere.

Abbott Labs, a large cap pharma company, currently carries a Zacks Rank #3 (Hold).  Right now, large cap pharma stocks that look well-placed include Bayer (BAYRY - Analyst Report) and Novo Nordisk (NVO - Analyst Report). Both carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%